Table 4 Evidence profile: SR1.2. Comparison of ACEI with ARB (effect of ARB to ACEI)
Certainty assessment | Number of patients | Effect | Certainty | Importance | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
No. of studies | Research design | Bias risk | Inconsistency | Indirectness | Inaccuracy | Other | CQ1.2 ARB | ACEI | Relative [95% CI] | Absolute (95% CI) | ||
Overall survival rate (number of deaths due to events) | ||||||||||||
1 | RCT | Serious a | Not serious | Not serious | Serious b | None | 0/30 (0.0%) | 0/30 (0.0%) | Cannot estimate | No change per 1000 patients (60 patients decreased to 60 patients increased) | ⨁⨁◯◯ Low | Critical |
Technical survival (PD continuation period/PD withdrawal) (PD withdrawal) | ||||||||||||
1 | RCT | Serious a | Not serious | Not serious | Serious b | None | 0/30 (0.0%) | 0/30 (0.0%) | Cannot estimate | No change per 1000 patients (60 patients decreased to 60 patients increased) | ⨁⨁◯◯ Low | Critical |
Technical survival (PD continuation period/PD withdrawal) (peritonitis) | ||||||||||||
1 | RCT | Serious a | Not serious | Serious c | Serious b | None | 7/30 (23.3%) | 6/30 (20.0%) | RR 1.17 [0.44–3.06] | 34 patients increased per 1000 patients (112 patients decreased to 412 patients increased) | ⨁◯◯◯ Very low | Important |
Urine volume/residual renal function (urine volume) | ||||||||||||
1 | RCT | Serious a | Not serious | Not serious | Serious b | None | 30 | 30 | - | MD 145 mL increase (8.35 mL decrease to 298.35 mL increase) | ⨁⨁◯◯ Low | Critical |
Urine volume/residual renal function (anuria) | ||||||||||||
1 | RCT | Serious a | Not serious | Not serious | Serious b | None | 12/30 (40.0%) | 11/30 (36.7%) | RR 1.09 [0.57–2.07] | 33 patients increased per 1000 patients (158 patients decreased to 393 patients increased) | ⨁⨁◯◯ Low | Critical |
Urine volume/residual renal function (GFR) | ||||||||||||
1 | RCT | Serious due | Not serious | Not serious | Serious b | None | 30 | 30 | - | MD 0.18 decrease (0.4 decrease to 0.04 increase) | ⨁⨁◯◯ Low | Critical |
Dialysis volume (total KT/V) | ||||||||||||
1 | RCT | Serious a | Not serious | Serious c | Serious b | None | 42 | 42 | - | MD 0.09 decrease (0.26 decrease to 0.08 increase) | ⨁◯◯◯ Very low | Important |
Complications (including drug adverse effects/safety issues/hospital stay period) (hyperkalemia) | ||||||||||||
2 | RCT | Serious a | Not serious | Not serious | Serious b | None | 6/72 (8.3%) | 5/72 (6.9%) | RR 1.20 [0.40–3.63] | 14 patients increased per 1000 patients (41 patients decreased to 181 patients increased) | ⨁⨁◯◯ Low | Important |
Complications (including drug adverse effects/safety issues/hospital stay period) (hospitalization) | ||||||||||||
1 | RCT | Serious a | Not serious | Serious c | Serious b | None | 4/30 (13.3%) | 5/30 (16.7%) | RR 0.80 [0.24–2.69] | 33 patients decreased per 1000 patients (127 patients decreased to 282 patients increased) | ⨁◯◯◯ Very low | Important |
Other outcomes deemed important by the CQ team (cardiovascular events) | ||||||||||||
1 | RCT | Serious a | Not serious | Not serious | Serious b | None | 4/30 (13.3%) | 3/30 (10.0%) | RR 1.33 [0.33–5.45] | 33 patients increased per 1000 patients (67 patients decreased to 445 patients increased) | ⨁⨁◯◯ Low | Critical |